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Objective: Randomized trials have shown an initial survival beneﬁt of endovascular over conventional open abdominal
aortic aneurysm repair but no long-term difference up to 6 years after repair. Longer follow-up may be required to
demonstrate the cumulative negative impact on survival of higher reintervention rates associated with endovascular
repair.
Methods: We updated the results of the Dutch Randomized Endovascular Aneurysm Management (DREAM) trial, a
multicenter, randomized controlled trial comparing open with endovascular aneurysm repair, up to 15 years of follow-up.
Survival and reinterventions were analyzed on an intention-to-treat basis. Causes of death and secondary interventions
were compared by use of an events per person-year analysis.
Results: There were 178 patients randomized to open and 173 to endovascular repair. Twelve years after randomization,
the cumulative overall survival rates were 42.2% for open and 38.5% for endovascular repair, for a difference of 3.7 per-
centage points (95% conﬁdence interval, 6.7 to 14.1; P ¼ .48). The cumulative rates of freedom from reintervention were
78.9% for open repair and 62.2% for endovascular repair, for a difference of 16.7 percentage points (95% conﬁdence in-
terval, 5.8-27.6; P ¼ .01). No differences were observed in causes of death. Cardiovascular and malignant disease account
for the majority of deaths after prolonged follow-up.
Conclusions: During 12 years of follow-up, there was no survival difference between patients who underwent open or
endovascular abdominal aortic aneurysm repair, despite a continuously increasing number of reinterventions in the
endovascular repair group. Endograft durability and the need for continued endograft surveillance remain key
issues. (J Vasc Surg 2017;66:1379-89.)Three of the four randomized trials comparing elective
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ARTICLE HIGHLIGHTS
d Type of Research: Prospective Dutch Randomized
Endovascular Aneurysm Management (DREAM) trial
d Take Home Message: At 12 years, the cumulative
overall survival rates were 42.2% for open repair
and 38.5% for endovascular aneurysm repair (EVAR)
of abdominal aortic aneurysm (P ¼ .48). The cumula-
tive rates of freedom from reintervention were 78.9%
for open repair and 62.2% for EVAR (P ¼ .01).
d Recommendation: At 12 years, there was no differ-
ence in survival between open abdominal aortic
aneurysm repair and EVAR, in spite of the increasing
number of reinterventions after EVAR. Continued
follow-up is recommended because of concerns of
durability of EVAR and the need for reinterventions.
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currently available may be required to demonstrate this
effect. Similarly, 5- to 6-year follow-up may be too short
to identify low-incidence durability issues of endografts
as well as to evaluate the cumulative effects of repeated
exposure to radiation and doses of iodinated contrast
agents that are a part of the obligatory endograft surveil-
lance computed tomography (CT) scans.8,9 Therefore,
12 years after the last patient was enrolled and 7 years
after data acquisition was stopped, we updated survival
and reintervention rates in participants of the DREAM
trial.
METHODS
Study design. The design and methods of the trial have
been described in detail elsewhere.10 In brief, the DREAM
trial was a multicenter, randomized trial conducted at 26
centers in The Netherlands and 4 centers in Belgium. The
Institutional Review Board at each center approved
the original trial protocol and the follow-up extension.
In the protocol, a late analysis of cumulative survival rates,
secondary interventions, and causes of death was
prescheduled. The study was performed according to
the principles of the Declaration of Helsinki.
Study patients. Patients who had an asymptomatic
abdominal aortic aneurysm measuring at least 5 cm in
diameter and who were considered suitable candidates
for either open or endovascular repair were enrolled after
providing written informed consent. Further eligibility for
inclusion in the DREAM trial and randomization proced-
ure were described previously.10
The primary informed consent covered 2 years of close
follow-up for all patients. For subsequent long-term
analysis, a second written informed consent was
obtained from all patients who had completed the initial
2 years of follow-up.5
Data collection. The previous data acquisition had
stopped on February 1, 2009.5 For the 229 patients
reported to be alive at that moment, all relevant infor-
mation from the medical records as of enrollment were
reviewed at the participating centers. Data retrieved
included history and physical examination at ofﬁce visits,
imaging reports, laboratory results, operative reports, and
all available data from other specialists and hospitals.
Records were scrutinized for information about survival
status, causes of death, and secondary procedures.
Additional information on causes and date of death was
obtained by reviewing death certiﬁcates and contacting
involved physicians (surgeons or general practitioners).
Patients or relatives were contacted by telephone, and
with their approval and to the best of their ability, infor-
mation was obtained about physical and mental health,
secondary interventions, and, if applicable, date and
cause of death. Cause of death and secondary interven-
tion information were crossmatched with the dataobtained from the patient’s medical record and from
consultation with the patient’s primary care physician.
Data collection ended on January 5, 2016.
For this analysis, all data were censored at the last date
of contact (by telephone or follow-up). All information
was integrated with data from our preceding analysis.5
End points. The long-term outcomes analyzed were
death from all causes, aneurysm-related mortality, and
secondary procedures.
Causes of death were grouped as follows: aneurysm
related; cardiovascular, nonaneurysm related (myocar-
dial infarction, cardiac arrest, congestive heart failure,
stroke, and other cardiovascular); malignant disease;
respiratory disease; miscellaneous; and unknown.
Unknown causes of death included “natural cause” on
death certiﬁcates and missing records of both trial
centers and general practitioners.
Aneurysm-related mortality was deﬁned as any death
within 30 days of the initial repair or any secondary inter-
vention, or during the hospitalization of these proced-
ures, or any late death adjudicated as having resulted
directly or indirectly from the aneurysm or its treatment.
A secondary procedure or reintervention was deﬁned as
any surgical or endovascular procedure performed after
and directly or indirectly related to the primary aneurysm
repair procedure. The indication for a secondary inter-
vention was at the discretion of the individual surgeon.
Secondary procedures were classiﬁed by indication into
three groups: (1) aneurysm related, including incomplete
aneurysm exclusions (endoleak of any type, rupture, and
migration), para-anastomotic aneurysms, thrombo-
occlusive events, and prosthesis infections; (2) wound
related, including incisional hernia, burst abdomen
(abdominal wound dehiscence in which intestine,
omentum, or other viscera are visible), and wound infec-
tion; and (3) local or systemic, including bleeding, laparo-
scopic or laparotomic adhesiolysis or bowel resection
Fig 1. Consolidated Standards of Reporting Trials diagram. Randomization, distribution, and survival numbers.
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stenting, iatrogenic ureteral damage, and necrotizing
cholecystitis.
An outcome adjudication committee, consisting of
vascular surgeons, classiﬁed the causes of death and
reinterventions in a blinded fashion and independently
from each other. Disagreements were resolved in a
plenary consensus meeting.
Data analysis. All data were analyzed according to the
intention-to-treat principle. The completeness of follow-
up was calculated as the ratio of the total observed
person-time of follow-up to the potential time of follow-
up in the study.11 Kaplan-Meier analysis was used to
calculate survival and freedom from reintervention.
Differences between groups were compared with the
use of the log-rank test.
To investigate a time-dependent variation in the rate of
causes of death and secondary procedures, three follow-
up periods were distinguished, roughly corresponding to
(1) the episode of early endovascular beneﬁt (0-6 months
after randomization, including the preoperative periodand hospitalization after initial aneurysm treatment),
(2) the episode of overlapping survival rates in the previ-
ous midterm analysis (6 months to 6 years after random-
ization), and (3) the new prolonged follow-up episode
between 6 and 15 years after randomization. For each
episode and event, person-years at risk and events per
100 person-years per randomized group were calculated.
Conditional maximum likelihood estimate rate ratios
were calculated by dividing the event rate per 100
person-years after open repair by the event rate per 100
person-years after endovascular repair. Conﬁdence inter-
vals (CIs) and statistical differences of rate ratios were
calculated using OpenEpi.com.
All reported P values are two sided without correction
for multiple testing.
RESULTS
Patient characteristics and follow-up. Between
November 2000 and December 2003, 178 patients
were randomly assigned to undergo open repair and
173 to undergo endovascular repair (Fig 1). Baseline
characteristics are shown in Table I. The mean age of the
Table I. Baseline characteristics of the patients
Characteristic Open repair (n ¼ 178) Endovascular repair (n ¼ 173) P value
Age, years 69.6 6 6.8 70.7 6 6.6 .13
Male sex 161 (90) 161 (93) .44
Mild, moderate, or severe SVS/ISCVS risk factor scorea
Diabetes mellitus 9.6 10.4 .86
Tobacco use 55.1 64.2 .10
Hypertension 54.5 58.4 .52
Hyperlipidemia 52.6 47.0 .33
Carotid disease 15.2 14.5 .88
Cardiac disease 46.6 41.0 .33
Renal disease 8.4 7.5 .85
Pulmonary disease 18.5 27.7 .04
Sum of SVS/ISCVS risk factor scoresa 4.5 6 2.5 4.4 6 2.5 .61
FEV1, L/s 2.6 6 0.7 2.5 6 0.7 .27
Body mass index, kg/m2 26.6 6 4.1 26.3 6 3.4 .47
ASA class
1 Healthy status 44 (25) 37 (22) .53
2 Mild systemic disease 110 (62) 122 (71) .09
3 Severe systemic disease 24 (14) 14 (8) .12
Medication use
b-Adrenergic blockers 92 (52) 76 (44) .17
Statinsb 72 (42) 63 (37) .44
Antiplatelet agents 72 (40) 70 (41) 1.00
Angiotensin-converting enzyme inhibitors 50 (28) 58 (34) .30
Calcium channel blockers 32 (18) 30 (17) .89
Anticoagulants 27 (15) 20 (12) .35
ASA, American Society of Anesthesiologists; FEV1, forced expiratory volume in 1 second.
Categorical variables are presented as number (%). Continuous variables are presented as mean 6 standard deviation. Because of rounding, not all
percentages total 100.
aThe Society for Vascular Surgery/International Society for Cardiovascular Surgery (SVS/ISCVS) risk factor score ranges for each of eight domains from
0 (no risk factors) to 3 (severe risk factors). Total scores can range from 0 to 24, with higher scores indicating more risk factors.
bNo information was available for six patients in the open repair group and four patients in the endovascular repair group.
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concomitant cardiac disease.
In the open repair group, 166 patients were discharged
from the hospital (including 1 without repair and 4 after
endovascular repair); in the endovascular repair group,
169 patients were discharged from the hospital
(including 4 after open repair; Fig 1). The median follow-
up was 10.2 years (quartile range, 5.0-12.5 years).
The completeness of follow-up was 98.4% (37.177/
37.775months) forallpatients,98.9%(19.054/19.267months)
for open repair, and 97.9.% (18.123/18.507 months) for
endovascular repair. Eight patients were lost to follow-up,
three (1.7%) after open and ﬁve (2.9%) after endovascular
repair.
Long-term aneurysm surveillance after the 2 years of
close follow-up prescribed by the DREAM trial protocol
varied by institution. Nevertheless, most surviving
patients were still actively scheduled for return visits
5 years after inclusion in the trial. The median durationof local outpatient surveillance was 5.1 years after open
repair compared with 5.8 years after endovascular repair.
At 5 years, 77.5% of surviving patients in the open repair
group had visited their vascular surgeon compared
with 90.0% in the endovascular repair group. At this
time point, only about one-fourth of patients in the
open repair group had had abdominal CT angiography
compared with almost all patients in the endovascular
repair group. After 10 years, 22.5% of surviving patients
in the open repair group and 68.3% in the endovascular
repair group remained under active surveillance. These
rates had dropped to 11.3% and 50% by 12 years,
respectively.
Survival. Twelve years after randomization, the cumula-
tive overall survival rates were 42.2% for open repair and
38.5% for endovascular repair, for a difference of 3.7
percentage point (95% CI, 6.7 to 14.1; P ¼ .48; Fig 2, A).
Of all patients, 50.2% were still alive 10 years after inclu-
sion in the trial.
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Fig 2. A, Kaplan-Meier estimates of survival among patients assigned to undergo open surgical repair (OSR) or
endovascular aneurysm repair (EVAR). B, Kaplan-Meier estimates of freedom from reintervention among pa-
tients assigned to undergo OSR or EVAR. C, Kaplan-Meier estimates of intervention-free survival among patients
assigned to undergo OSR or EVAR. LFU, Lost to follow-up; NAR, number at risk.
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Volume 66, Number 5We were unable to crossmatch the causes of 12 of 220
(5%) deaths. In four cases, the cause of death communi-
cated by family members could not be veriﬁed because
of documentation or general practitioners being unavai-
lable or patients having moved abroad. In eight cases, no
information about cause of death was obtained from
general practitioners or family members.
No differences were observed in aneurysm-relatedmor-
tality between groups 12 years after randomization: 7.7%
after open repair and 3.1% after endovascular repair, for a
difference of 4.6 percentage points (95% CI, 9.6 to 0.4;
P ¼ .33). In the ﬁrst 6 months, deaths were predominantly
classiﬁed as aneurysm related (Table II). In contrast to the
initial advantage for endovascular repair in terms of
aneurysm-related mortality, no signiﬁcant differences
were found in all-cause mortality, aneurysm-related mor-
tality, or mortality due to cardiovascular or malignant dis-
ease in the long term.
Beyond 6 years of follow-up, more patients died of pul-
monary diseases in the open repair group (11 patients or
1.7 events per 100 person-years) compared with the
endovascular repair group (2 patients or 0.3 event per
100 person-years), for an event rate ratio of 6.0 (95% CI,
1.49-39.9; P < .01; Table II).
There were four deaths from aneurysm rupture, two in
each randomization group. One of the ruptures occurred
before surgery in a patient randomized to open repair and
another in a patient who had crossed over to endovascular
repair, so all three postoperative deaths from aneurysm
rupture occurred after endovascular repair. Besides these
fatal aneurysm ruptures, one additional patient in the endo-
vascular repair group survived ruptured aneurysm repair.
Secondary procedures. Twelve years after randomiza-
tion, the cumulative rates of freedom from secondary
procedure were 78.9% for open repair and 62.2% for
endovascular repair, for a difference of 16.7 percentage
points (95% CI, 5.8-27.6; P ¼ .01; Fig 2, B).Reintervention-free survival was 34.9% for open repair
and 26.5% for endovascular repair 12 years after random-
ization, for a difference of 8.4 percentage points (95%
CI, 1.3 to 18.11; P ¼ .13; Fig 2, C).
The accumulation of all secondary procedures,
including multiple reinterventions per patient, is
depicted in Fig 3. In total, 143 secondary procedures
were performed in 87 patients, 44 secondary procedures
in 33 patients in the open repair group (2.8 events per 100
person-years) and 99 secondary procedures in 54 pa-
tients in the endovascular repair group (6.6 events per
100 person-years), for an event rate ratio of 0.42 (95%
CI, 0.30-0.60; P < .001; Table III). This difference was pre-
dominantly determined by aneurysm-related indica-
tions, speciﬁcally reinterventions for incomplete
aneurysm exclusion (event rate ratio of 0.04; 95% CI,
0.01-0.14; P < .001) and thrombo-occlusive indications
(event rate ratio of 0.28; 95% CI, 0.10-0.68; P < .01;
Table III).
Although secondary procedures in the endovascular
repair group continued to be performed throughout
the entire follow-up, the event rate per 100 person-
years dropped from 24.7 (95% CI, 15.3-37.7) in the ﬁrst
6 months to 6.4 (95% CI, 4.8-8.5) in the midterm and 3.7
(95% CI, 2.5-5.5) in the subsequent long-term episode.
An increased intervention rate is observed after 4 years
of follow-up (Fig 2, B). This period was characterized by
secondary interventions related to endograft durability.
In this period, 12 procedures were performed because
of an incomplete aneurysm exclusion and 4 for
thrombo-occlusive disease. Of these interventions, one
was performed in a patient with a ruptured aneurysm
and one with a symptomatic aneurysm.
Conversion from endovascular to open repair occurred
in 19 patients (1.2 events per 100 person-years; 95% CI,
0.7-1.8), with an event rate dropping from 5.9 (95% CI,
2.2-13.0) in the ﬁrst 6 months to 0.3 (95% CI, 0.1-0.9)
beyond 10 years.
Table II. Causes of death after open repair and endovascular aneurysm repair (EVAR)
Cause of death
No. entering period
No. lost to follow-up
0-6 months
RRa (95% CI) P value
>6 months-6 years
Open repair
(n ¼ 178)
EVAR
(n ¼ 173)
Open repair
(n ¼ 168)
EVAR
(n ¼ 167)
Event incidence (incidence rate/100 person-years)
Any cause 10 (11.7) 6 (7.1) 1.65 (0.60-4.90) .34 43 (5.1) 48 (6.1)
Aneurysm related 10 (11.7) 3 (3.5) 3.31 (0.96-14.93) .06 2 (0.2) 2 (0.3)
Rupture 1d 0 Undeﬁned .50 1i 0
Infection prosthesis 2 0 Undeﬁned .25 0 2
Other, <30 days of procedurec 7e 3f 2.31 (0.61-11.01) .23 1j 0
Cardiovascular, not aneurysm related 0 (0) 1 (1.2) 0 (0.0-18.84) .50 14 (1.6) 12 (1.5)
Myocardial infarction 0 0 0 0 4 2
Cardiac arrest 0 0 0 0 2 3
Congestive heart failure 0 0 0 0 4 5
Stroke 0 0 0 0 4 2
Other cardiovascular 0 1g 0 (0.08-18.84) .50 0 0
Malignant disease 0 (0) 1 (1.2) 0 (0.08-18.84) .50 15 (1.7) 16 (2.0)
Pulmonary disease 0 (0) 1h (1.2) 0 (0.08-18.84) .50 3 (0.4) 5 (0.6)
Miscellaneous 0 (0) 0 (0) 0 0 3k (0.4) 7l (0.8)
Unknown 0 (0) 0 (0) 0 0 6 (7.1) 6 (7.6)
CI, Conﬁdence interval; RR, rate ratio.
aConditional maximum likelihood estimate rate ratio: the ratio between the overall event incidence rate per 100 person-years after open repair
divided by the overall event incidence rate per 100 person-years after endovascular repair.
bRate ratio: P < .05.
cWithin 30 days of the initial repair or any secondary intervention, or during the hospitalization of these procedures.
dThe cause of death was a ruptured abdominal aortic aneurysm before scheduled repair.
eThe causes of death were as follows: anastomotic bleeding, myocardial infarction, cardiac arrest, ischemic bowel, intraoperative anaphylactic shock,
multiorgan failure after repair of a burst abdomen, and progressive dementia.
fThe causes of death were as follows: myocardial infarction, bilateral pneumonia, and one not documented.
gThe cause of death was a pulmonary embolism, 3 months after discharge.
hThis patient died 84 days after randomization, before undergoing aneurysm repair, from pneumonia with pre-existent pulmonary ﬁbrosis.
iThe cause of death was a ruptured abdominal aortic aneurysm in a patient who had crossed over to endovascular repair.
jThe cause of death was a cardiac arrest 2 days after intervention.
kThe causes of death were gastrointestinal bleeding, sepsis after acute pancreatitis and cholangitis, and uremia after severe dehydration.
lThe causes of death were as follows: twice from a gastrointestinal bleeding, complications of diaphragmatic hernia repair, suicide, liver failure
associated with alcohol abuse, complications of hip fracture surgery, and dehydration from obstructive bowel disease.
mThe cause of death was systemic inﬂammatory response syndrome from Enterobacter pneumosepsis.
nThe causes of death were twice from dementia, a subdural hematoma, and cachexia.
oThe cause of death was dehydration from obstructive bowel disease.
pThe causes of death were as follows: ischemia of the lower leg and refusal of further treatment and a ruptured thoracic aneurysm.
qThe causes of death were as follows: three from dementia, subdural hematoma, major neurotrauma, urosepsis, and acute renal failure on dehy-
dration from diabetic foot.
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gical, 45 (31.5%) were endovascular procedures, 8 were a
hybrid of open and endovascular procedures, and 1 rein-
tervention was performed laparoscopically.
DISCUSSION
The principal ﬁnding after 12 to 15 years of follow-up
of this randomized study is that in patients with
infrarenal abdominal aortic aneurysms, there is no
signiﬁcant difference in overall survival between
open and endovascular repair, despite a continuously
increasing number of secondary procedures after
endovascular repair.
This study reconﬁrms that there is only an early
survival beneﬁt for endovascular repair as shown
previously by the DREAM trial and two of the threeother randomized trials comparing elective open
and endovascular repair of abdominal aortic aneu-
rysm (EVAR 1 and OVER, not ACE).1-4 Until recently,
the reported median follow-up of these trials was be-
tween 5.2 and 6.4 years.
We hypothesized that longer follow-up of the random-
ized trials would be required to demonstrate the cumu-
lative negative impact on overall survival from secondary
procedures after endovascular abdominal aortic aneu-
rysm repair. This study could not demonstrate such an
effect. The impact of the continuously increasing num-
ber of reinterventions, the durability issues of endovascu-
lar grafts, and the cumulative irradiation effects of the
increased use of CT for endograft surveillance did not
accumulate to a signiﬁcant survival disadvantage after
endovascular repair.
Table II. Continued.
RR (95% CI) P value
6-15 years
RR (95% CI) P value
Total
RR (95% CI) P valueb
Open repair
(n ¼ 125)
(n ¼ 2)
EVAR
(n ¼ 119)
(n ¼ 1)
Open repair
(n ¼ 175)
(n ¼ 3)
EVAR
(n ¼ 168)
(n ¼ 5)
Event incidence (incidence rate/100 person-years)
0.83 (0.55-1.26) .38 54 (8.3) 59 (8.3) 1.0 (0.69-1.45) 1.0 107 (6.7) 113 (7.5) 0.90 (0.69-1.17) .41
0.93 (0.10-8.92) .95 1 (0.2) 3 (0.4) 0.36 (0.01-3.41) .42 13 (0.8) 8 (0.5) 1.54 (0.64-3.90) .35
Undeﬁned .52 0 2 0.0 (0.0-3.79) .27 2 2 0.95 (0.09-9.09) .96
0.0 (0.0-3.23) .23 0 0 0.0 0 2 2 0.95 (0.09-9.09) .96
Undeﬁned .52 1m 1o 1.09 (0.03-42.61) .96 9 4 2.13 (0.67-7.95) .21
1.08 (0.50-2.40) .84 14 (2.1) 11 (1.5) 1.39 (0.63-3.15) .42 28 (1.8) 24 (1.6) 1.10 (0.64-1.92) .73
1.86 (0.33-14.51) .51 3 3 1.09 (0.19-6.36) .92 7 5 1.32 (0.41-4.56) .65
0.62 (0.07-4.17) .63 2 1 2.19 (0.17-64.45) .58 4 4 0.95 (0.21-4.19) .94
0.74 (0.18-2.93) .67 6 2 3.28 (0.69-23.59) .14 10 7 1.35 (0.51-3.76) .55
1.86 (0.33-14.51) .51 3 3 1.09 (0.19-6.36) .92 7 5 1.32 (0.41-4.56) .65
0.0 0 0 2p 0.0 (0.0-3.79) .27 0 3 0.00 (0.00-1.62) .11
0.87 (0.42-1.78) .70 14 (2.1) 19 (2.7) 0.81 (0.39-1.61) .54 29 (1.8) 36 (2.4) 0.76 (0.46-1.24) .28
0.56 (0.11-2.41) .45 11 (1.7) 2 (0.3) 6.01 (1.49-39.91) <.01 14 (0.9) 8 (0.5) 1.66 (0.70-4.16) .26
0.40 (0.08-1.52) .19 4n (0.6) 7q (1.0) 0.62 (0.16-2.16) .47 7 (0.4) 14 (0.9) 0.47 (0.18-1.16) .10
0.93 (0.28-3.05) .90 10 (1.5) 17 (2.4) 0.64 (0.28-1.40) .27 16 (1.0) 23 (1.5) 0.66 (0.34-1.25) .20
Fig 3. Cumulative number of secondary procedures over
time. The solid lines reﬂect all reinterventions and the
dashed lines only the ﬁrst reintervention in a patient.
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group, increased mortality after endovascular repair
was demonstrated beyond 8 years following randomi-
zation.12 This effect was caused by a higher risk of
rupture and aneurysm-related mortality. In addition,
malignant disease was seen more frequently as a
cause of death after endovascular repair. This phe-
nomenon might potentially be explained by ionizing
radiation during aggressive surveillance of endografts.
Regarding this hypothesis, we did ﬁnd a nonsigniﬁcant
larger number of cancer deaths in the endovascularrepair group, particularly in the long term; our data,
however, did not provide further evidence to that of
the EVAR 1 trial for an association between long-
term cancer deaths after endovascular repair and an
increased dose of CT-related radiation.8,9,12
When analyzing causes of death in speciﬁc follow-up
time frames, we demonstrated a time-dependent
variation. After the known initial survival beneﬁt of
endovascular repair in the ﬁrst 6 months and the
subsequent disappearance of this advantage in the
midterm between 6 months and 6 years, a further
parallel course of the survival curves beyond 6 years
is noticed.
Despite the fact that we did not observe an
increased aneurysm-related mortality, the occurrence
of death due to aneurysm rupture beyond 6 years
of follow-up in two patients after endovascular repair
illustrates the lack of durability and emphasizes
the need for continued close surveillance of endog-
rafts. This problem is reinforced by the number of
stent-related secondary interventions after endo-
vascular repair in the period beyond 6 years after
randomization.
Although we have shown durability issues of endografts
over the entire follow-up period and a persistent
increased risk of secondary intervention, this does not
amount to a signiﬁcant overall survival disadvantage
after endovascular repair.
Table III. Indications for secondary procedure after open repair and endovascular aneurysm repair (EVAR)
Indication for reintervention
No. entering period
No. lost to follow-up
0-6 months
RRa (95% CI) P value
>6 months-6 years
Open repair
(n ¼ 178)
EVAR
(n ¼ 173)
Open repair
(n ¼ 168)
EVAR
(n ¼ 167)
Event incidence (incidence rate/100 person-years)
Any indication 16 (18.6) 21 (24.7) 0.76 (0.39-1.45) .40 26 (3.1) 51 (6.5)
Aneurysm-related indication 2 (2.3) 14 (16.5) 0.14 (0.02-0.55) .002 9 (1.1) 38 (4.8)
Incomplete exclusion 0 10 0.0 (0.0-0.35) <.001 3 22
Para-anastomotic aneurysm 0 0 0.0 0 2 0
Prosthesis infection 0 0 0.0 .50 0 3
Thrombo-occlusive 2 4 0.50 (0.06-2.80) .44 4 13
Wound-related indication 4 (4.7) 2 (2.4) 1.98 (0.35-15.48) .46 16 (1.9) 9 (1.1)
Wound complications 1 2 0.50 (0.02-6.52) .62 0 4f
Incisional hernia 3 0 Undeﬁned .13 16 5
Local or systemic indication 10 (11.7) 5 (5.9) 1.98 (0.68-6.42) .22 1 (0.1) 4 (0.5)
Bleeding 6 3 1.98 (0.49-9.71) .35 1 1
Bowel resection or ileus 4c 1d 3.97 (0.50-98.15) .22 0 1g
Miscellaneous 0 1e 0.0 (0.0-18.84) .50 0 2h
CI, Conﬁdence interval; RR, rate ratio.
aConditional maximum likelihood estimate rate ratio: the ratio between the overall event incidence rate per 100 person-years after open repair
divided by the overall event incidence rate per 100 person-years after endovascular repair.
bRate ratio: P < .05.
cThe indications for secondary intervention were adhesiolysis because of bowel obstruction, a small bowel resection because of obstruction, a lap-
arotomy under suspicion of colonic ischemia, and a second repeated laparotomy after severe postoperative hemorrhage.
dThe reintervention was a repeated laparotomy for unexplained gastrointestinal pain.
eThe indication for reintervention was an infected femoral-femoral crossover.
fThe indications for reintervention were as follows: groin wound revision with scar excision in one, drainage of groin wound infection in one, and two
procedures in one patient for infection: drainage of an intra-abdominal abscess, later followed by a one-sided excision of a stent graft limb.
gThe reintervention was a laparoscopic biopsy because of retroperitoneal ﬁbrosis.
hThe indications for secondary intervention were a left-sided nephrectomy after ureter damage, caused by a laparoscopic retroperitoneal biopsy for
ﬁbrosis, and a delayed crossover to open repair after a failed endovascular attempt due to severe iliac stenosis.
iThe reintervention was adhesiolysis for bowel obstruction.
jThe reintervention was a Hartmann procedure after aorta-sigmoidal ﬁstula secondary to conversion.
kThe reinterventions were renal artery bypass after proximal stent graft extension and overstenting of the renal artery due to stent graft migration,
secondary to Q fever aortitis in one, and cholecystectomy after necrotizing cholecystitis, secondary to conversion to open repair.
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November 2017More than 50% of our patients are still alive, 10 years
after inclusion in the trial, considering they all have at
least one manifestation of cardiovascular disease
(abdominal aortic aneurysm) and 44% had concomi-
tant cardiac disease. Furthermore, cardiovascular risk
management at the time of randomization was far
from optimal. For example, only 40% of patients
had statins prescribed at the time of randomization.
A recent review of literature proves an increased
cumulative long-term survival after open and endo-
vascular repair from adequate cardiovascular risk
management.13 Nonetheless, a population-based
Medicare study describing survival after open and
endovascular repair in the same time frame as the
DREAM trial showed overall survival rates after 8 years
in the range of 45%, whereas it is roughly 60% in the
DREAM trial cohort.14,15 Although a propensity score
matching was performed in this Medicare study, the
fact that all patients in the DREAM trial were suitable
for both open and endovascular repair may beresponsible for a better initial surgical risk and there-
fore better long-term overall survival.
We also reconﬁrm that secondary procedures after
endovascular repair continue to be an issue, whereas
reinterventions after open repair are unusual, even
with follow-up extending up to 15 years after random-
ization. The OVER trial showed no difference in rein-
terventions between open and endovascular repair
after a mean follow-up of 5.2 years,7 whereas the
EVAR 1 trial also showed a continuous decline of
freedom from secondary procedures after endovascu-
lar repair after a median follow-up of 12.7 years, with
reinterventions after open repair occurring only
sporadically after 2 to 3 years. However, the relative
difference in secondary intervention rate was pre-
eminent between hospital discharge and 4 years after
randomization.12
The combination of three new ﬁndings in this study is a
cause for concern. Not only do patients survive longer
than expected after aneurysm repair, with at least half
RR (95% CI) P value
>6-15 years
RR (95% CI) P value
Total
RR (95% CI) P valueb
Open repair
(n ¼ 125)
(n ¼ 2)
EVAR
(n ¼ 119)
(n ¼ 1)
Open repair
(n ¼ 175)
(n ¼ 3)
EVAR
(n ¼ 168)
(n ¼ 5)
Event incidence (incidence rate/100 person-years)
0.47 (0.29-0.76) .002 2 (0.3) 27 (3.7) 0.08 (0.01-0.29) <.001 44 (2.8) 99 (6.6) 0.42 (0.29-0.60) <.001
0.22 (0.10-0.44) <.001 1 (0.2) 22 (3.1) 0.05 (0.0-0.27) <.001 12 (0.8) 74 (4.9) 0.15 (0.08-0.27) <.001
0.13 (0.03-0.38) <.001 0 14 0.0 (0.0-0.26) <.001 2 46 0.04 (0.01-0.14) <.001
Undeﬁned .27 1 2 0.55 (0.02-7.18) .68 4 2 1.89 (0.34-14.77) .49
0.0 (0.0-1.59) .11 0 3 0.0 (0.0-1.87) .14 0 6 0.0 (0.0-0.61) .01
0.29 (0.08-0.84) .02 0 3 0.0 (0.0-1.87) .14 6 20 0.28 (0.10-0.68) .004
1.65 (0.73-3.91) .23 0 (0.0) 0 (0.0) 0.0 0 20 (1.3) 11 (0.7) 1.72 (0.83-3.72) .15
0.0 (0.0-1.04) .05 0 0 0.0 0 1 6 0.16 (0.01-1.07) .06
2.97 (1.13-9.08) .03 0 0 0.0 0 19 5 3.60 (1.40-10.79) .006
0.23 (0.01-1.85) .19 1 (0.2) 5 (7.0) 0.22 (0.01-1.58) .15 12 (0.8) 14 (0.9) 0.81 (0.37-1.77) .60
0.92 (0.02-36.24) .96 0 2 0.0 (0.0-3.79) .27 7 6 1.10 (0.36-3.50) .86
0.0 (0.0-17.65) .48 1i 1j 1.09 (0.03-42.61) .96 5 3 1.58 (0.36-8.01) .56
0.0 (0.0-3.23) .23 0 2k 0.0 (0.0-3.79) .27 0 5 0.0 (0.0-0.78) .03
Table III. Continued.
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tients in the endovascular repair group also continue to
be submitted to secondary procedures, and the risk of
death from aneurysm rupture is persistent over time.
This observation stresses the continued need for endo-
vascular graft surveillance, even beyond 6 years after
aneurysm repair. It also calls for awareness that durability
of endovascular grafts is still of utmost importance in
designing new devices for endovascular repair. Lower
proﬁle and wider indications should not be achieved at
the expense of higher risks for reintervention and the
need for more CT follow-up.
Several limitations of this study need to be addressed.
Even though the trial protocol referred to the most
recent clinical practice guidelines, reintervention rates
constitute a soft end point because the indication for a
secondary procedure was at the discretion of the
surgeon. In this respect, it is important to realize that
the approach to type II endoleak after endovascular
repair evolved over time. In the ﬁrst decade of theDREAM trial, a rather aggressive general stance toward
type II endoleak possibly led to many reinterventions
that in more recent times would not have been consid-
ered appropriate.16 On the other hand, the long-term
fate of type II endoleak has not been elucidated, and
currently there is still inadequate information to support
a uniform approach to this problem.17,18
Since the initiation of this trial, endovascular devices
and techniques have undergone further modiﬁcation,
aiming at safer and more effective aneurysm exclusion
and better durability. The majority of the devices used
in this trial are no longer available on the market or
have been replaced by more durable systems. This limits
the generalizability of the reintervention rates in this
report and possibly the associated long-term survival
rates.
Although we acknowledge the fact that the endografts
used in this trial are outdated, we think this is an inevi-
table consequence of studying for long-term durability.
Expanding technical possibilities allow surgeons to
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November 2017choose an endovascular approach in patients with more
challenging anatomy. This in combination with the use
of new, lower proﬁle devices has the potential of further
compromising durability of endovascular repair.
Because four times the number of patients in the endo-
vascular repair group remained under active outpatient
surveillance compared with the open repair group, there
is a risk of ascertainment bias. This may have contributed
to increased discovery of graft-related complications af-
ter endovascular repair as opposed to open repair. Never-
theless, it is unlikely that clinically signiﬁcant problems
after open repair remain undetected for as long as
12 years. Furthermore, surveillance after the initial trial
period was based on clinical practice guidelines and
reﬂects standard clinical practice in patients who are
treated for abdominal aneurysms in The Netherlands.
Although differences in daily practice of endograft
surveillance cannot be excluded, similar rates of follow-
up were described in the long-term analysis of the
EVAR 1 trial.12
CONCLUSIONS
In the ﬁrst 6 months after randomization to either open
or endovascular repair of abdominal aortic aneurysms,
there is an overall survival beneﬁt for endovascular repair.
During the subsequent 12 years of follow-up, we did not
ﬁnd a signiﬁcant difference in overall survival or
aneurysm-related mortality, despite a persisting rate of
secondary procedures after endovascular repair.
Whereas no differences in causes of death were
observed, endograft durability issues are suggested to
contribute to a persistent risk of rupture and increased
rate of secondary interventions up to 15 years of follow-
up. This calls for continued vigilant endograft surveillance
extending well into the second decade after aneurysm
repair, using follow-up protocols with the least possible
amount of ionizing radiation, and for a renewed aware-
ness that endograft durability is of utmost importance
in future device design.
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